Product Images Silodosin

This is a prescription medication called Silodosin Capsules with the dosage strength of 4 mg. The recommended dosage is one capsule taken orally once daily with food. The package insert contains the full prescribing information. The medication should be stored at a controlled room temperature and protected from light and moisture. It is manufactured by MSN Laboratories Private Limited in Telangana, India and distributed by MSN Pharmaceuticals Inc. in Piscataway, NJ, USA. The medication has an NDC number of 69539-052-99 and was issued in December 2020.*

Silodosin Capsules are a prescription medication that come in a bottle of 30 capsules, each containing 4mg of Silodosin. The usual dosage is 1 capsule to be taken orally once a day, following the prescribing information mentioned in the package insert. The capsules should be stored at a temperature between 25°C-30°C (77°F-86°F) and protected from light and moisture. They are manufactured by MSH Laboratories Private Limited in India and distributed by WSN Pharmaceuticals, Inc in Piscataway, NJ. This information was issued in 12/2020.*

Silodosin Capsules are a medication with an NDC of 69539-052 that comes in a 90 capsule bottle. Each capsule contains 4mg of the active ingredient, Silodosin. The recommended dosage is one capsule once a day with a meal. The medication should be stored at 25°C (77°F) with excursions permitted for 15-30°C (59-86°F). Protect it from light and moisture, and keep it out of the reach of children. It was manufactured by MSN Laboratories Private Limited in Telangana, India, and distributed by WSN Pharmaceuticals Inc. in Piscataway, New Jersey. The product was issued in December 2020 with the MLNo: SIMNITSIR2014/F/G.*

Silodosin Capsules are a prescription drug indicated for the treatment of symptoms associated with BPH or benign prostatic hyperplasia. It comes in a package with 1000 capsules, each containing 8 mg silodosin. The usual dosage is one capsule orally once a day with a meal. This medicine needs to be stored and dispensed at controlled room temperature to protect it from light and moisture at 25°C. The manufacturer of Silodosin Capsules is WSN Laboratories Private Limited located in Telangana, India, while it is distributed in Piscataway, New Jersey, by MSN Pharmaceuticals Inc. Its full prescribing information can be found in the package insert.*

Silodosin Capsules are a prescription medication prescribed for adults only. The capsules come in a bottle pack of 30 and each capsule contains 8 mg of Silodosin. The usual recommended dosage is one capsule per day with food. The medicine should be stored at a controlled room temperature between 15 to 30°C, protected from light and moisture. The medicine should be kept away from children’s reach. The manufacturer of the medicine is MSN Laboratories Private Limited located in Telangana, India and distributed by MSN Pharmaceuticals Inc. located in New Jersey, USA. The medication should be used as directed and patients should refer to the package insert for full prescribing information.*

Silodosin Capsules are a prescription medication containing 8mg of silodosin per capsule. The usual dosage is 1 capsule orally with a meal once daily. It is manufactured by MSN Laboratories Private Limited in Telangana, India, and distributed by MSN Pharmaceuticals Inc. in New Jersey, USA. The medication should be stored at room temperature and protected from light and moisture. Full prescribing information is available in the package insert, and it should be kept out of reach of children.*

The text is describing a change in the IPSS (International Prostate Symptom Score) Total Score over a period of 84 days or LOCF (last observation carried forward). The change is statistically significant (p<0.0001). There are also numbers listed representing the baseline score and scores on days 35, 7, and 14. However, without context, it's hard to determine the meaning of these scores.*

The text describes a change in the International Prostate Symptom Score (IPSS) Total Score from a Baseline. The statistical significance of the change is highlighted with p<0.0001. The remaining text is not legible due to inconsistencies in the characters and format.*

The text describes a graph or table showing the change from baseline in Qmax (maximum urine flow) in mL/sec. There is a note indicating statistical significance (*p<0.05) for a comparison between AAA placebo and an unspecified treatment at 8mg. The graph or table appears to have data points at 1, 7, 14, 28, and 84 days, with LOCF (last observation carried forward) analysis.*